Novo Nordisk acquires late-stage kidney drug for up to $1.3B

Novo Nordisk is buying ocedurenone, an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA).

Related Keywords

Denmark ,United States ,Danish ,Americans ,Martin Holst Lange ,Eli Lilly Jardiance ,Inversago Pharma ,Drug Administration ,Novo Nordisk ,Novartis ,Development At Novo Nordisk ,Holst Lange ,Embark Laboratories ,Chinook Therapeutics ,Eli Lilly ,